Oak Thistle LLC Takes $2.44 Million Position in Insulet Corporation $PODD

Oak Thistle LLC acquired a new position in shares of Insulet Corporation (NASDAQ:PODD) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 7,887 shares of the medical instruments supplier’s stock, valued at approximately $2,435,000.

A number of other institutional investors have also recently bought and sold shares of the company. Norges Bank acquired a new position in Insulet in the 2nd quarter worth about $324,689,000. Qube Research & Technologies Ltd bought a new position in Insulet during the second quarter valued at approximately $131,439,000. Worldquant Millennium Advisors LLC acquired a new stake in Insulet in the second quarter valued at approximately $80,082,000. Kayne Anderson Rudnick Investment Management LLC lifted its stake in Insulet by 1,316.5% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier’s stock valued at $50,818,000 after acquiring an additional 179,850 shares during the last quarter. Finally, AustralianSuper Pty Ltd grew its position in Insulet by 487.5% in the second quarter. AustralianSuper Pty Ltd now owns 205,168 shares of the medical instruments supplier’s stock worth $64,460,000 after acquiring an additional 170,247 shares in the last quarter.

Analyst Upgrades and Downgrades

PODD has been the topic of a number of recent research reports. Stifel Nicolaus started coverage on shares of Insulet in a report on Tuesday, October 21st. They set a “buy” rating and a $370.00 price target on the stock. Rothschild & Co Redburn increased their target price on shares of Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a research report on Friday, October 3rd. Evercore ISI began coverage on Insulet in a report on Tuesday. They set an “outperform” rating and a $370.00 target price on the stock. Sanford C. Bernstein reiterated an “outperform” rating on shares of Insulet in a research note on Friday, November 21st. Finally, Raymond James Financial increased their price objective on Insulet from $366.00 to $385.00 and gave the company an “outperform” rating in a report on Friday, November 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $379.19.

Insulet Stock Down 1.0%

Insulet stock opened at $288.73 on Wednesday. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18. Insulet Corporation has a fifty-two week low of $230.05 and a fifty-two week high of $354.88. The firm has a fifty day moving average price of $317.99 and a two-hundred day moving average price of $314.34. The firm has a market cap of $20.31 billion, a price-to-earnings ratio of 83.69, a P/E/G ratio of 2.05 and a beta of 1.37.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The business had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. During the same period in the previous year, the company posted $1.08 earnings per share. The firm’s revenue for the quarter was up 29.9% on a year-over-year basis. As a group, analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.